About Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. The company is developing a powerful new class of potent, specific and versatile small protein therapies called DARPins.
Missing: Molecular Partners's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Molecular Partners's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Molecular Partners Patents
Molecular Partners has filed 1 patent.
Animal virology, Animal viral diseases, Virus families, Coronaviridae, Zoonoses
Animal virology, Animal viral diseases, Virus families, Coronaviridae, Zoonoses
Latest Molecular Partners News
Nov 16, 2022
11/16/2022 | 03:39pm EST Message : November 2022 1 Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constituteforward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates, including expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinicaltrials, expectations regarding interactions with regulatory authorities, the potential therapeutic and clinicalbenefits of Molecular Partners' product candidates, the selection and development of future antiviral or other programs, or other potential business development opportunities for product candidates, and Molecular Partners' expected expenses and cash utilization for 2022 and that its current cash resources will be sufficient to fund its operations and capital expenditure requirements into 2026. These statements may be identified by words such as "anticipate", "believe", "could", "expect", "intend", "may", "plan", "potential", "will", "would" and similar expressions, although not al l forward-looking statements may contain these identifying words, and are based on Molecular Partners' current beliefs and expectations. Thesestatements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Someof the key factors that could cause actual results to differ from our expectations include Molecular Partners' or its collaborators' plans to develop and potentially commercializeits product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinicalstudies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinicaltrials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achievemarket acceptance of Molecular Partners' product candidates; the potential impact of the COVID-19pandemic or other geopolitical events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; the adequacy of Molecular Partners' cash resources and our anticipated cash utilization; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 15, 2022, and other filings Molecular Partners makes with the SEC. These documents are available on the Investors page of Molecular Partners' website at http://www.molecularpartners.com . Any forward-looking statements speak only as of the date of this presentation and are based on information available to Molecular Partners as of the date of this presentation, and except to the extent required by law, Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. 2 On track to reach clinical initiation by end 2022 Oral presentation at ASH 2022 Abicipar: Reviewing path forward outside MP MP0317: Bi-specific CD40 local agonist In Phase 1 - enrollment ongoing at 3 mg/kg dose level Positive initial data presented at SITC DARPin-radioligand therapies: Internal research - ongoing with initial targets nominated in H1 23 Operational Highlights: Consistent, disciplined spend rate
Molecular Partners Web Traffic
Molecular Partners Rank
Molecular Partners Frequently Asked Questions (FAQ)
When was Molecular Partners founded?
Molecular Partners was founded in 2004.
Where is Molecular Partners's headquarters?
Molecular Partners's headquarters is located at Wagistrasse 14, Zurich.
What is Molecular Partners's latest funding round?
Molecular Partners's latest funding round is IPO.
How much did Molecular Partners raise?
Molecular Partners raised a total of $60.6M.
Who are the investors of Molecular Partners?
Investors of Molecular Partners include Endeavour Vision, Johnson & Johnson Innovation, Medicxi Ventures, BB Biotech Ventures, EW Healthcare Partners and 3 more.
Who are Molecular Partners's competitors?
Competitors of Molecular Partners include Sirnaomics, Pfenex, MOgene LC, Catalyst Biosciences, BioForce Nanosciences and 12 more.
Compare Molecular Partners to Competitors
Bar Harbor Biotech is a life sciences company spun-out from The Jackson Laboratory to develop gene expression products and services. Bar Harbor Biotech's technology focuses on real-time quantitative polymerase chain reaction (PCR), an established technique for gene expression used in disease research, molecular diagnostics, drug discovery, and other fields of biology research.
Synaptic Research LLC is a biotechnology company which conducts research and develops products based on naturally-occurring large protein molecules. Specifically, the company engineers proteins derived from toxins which affect the synaptic junction. A well-known example of such a protein is the Botulinum Neurotoxin, or BoNT. This protein has qualities of targeting and persistence which make it an excellent candidate for further engineering and development of therapeutic and pharmaceutical products.
ProteoGen Bio aims to join research and market in the fields of bioinformatics and biotechnology. Established in September 2003 as a spin-off company of the University of Pisa, with its expertise in different areas, and a interdisciplinary approach, ProteoGen Bio is developing technologies for helping modern molecular biology in its multi-purpose applications: from diagnostics to biomedicine, from mass spectrometry to environmental conservation.
Vybion is a developer and manufacturer of recombinant proteins for therapeutic and diagnostic applications. It uses its technologies along with a highly skilled staff to develop therapeutics, vaccines, diagnostics and bioavailability for pharmaceutical and biotechnology companies.
Nuclea Biotechnologies is a healthcare company dedicated to the development and commercialization of clinical diagnostic assays identifying gene and protein expression profiles characteristic of an individual's tumor or disease. Nuclea is committed to advancing discovery and validation of clinical test platforms that are predictive of a cancer patient\'s responsiveness to oncology therapeutics and the likelihood of disease recurrence. The Company utilizes translational medicine-based technology to refine the understanding of the biological principles underpinning human disease, enabling the discovery of disease specific biomarkers. The tests developed identify a patient\'s predictive response to a particular therapy or assess the risk of the disease developing or recurring later in life. Test results deliver valuable genetic information on the specific disease guiding treatment decisions.
Neugenesis Corporation is focused on generating better biotherapeutics, cost-effectively. To this end, Neugenesis has developed technology for the discovery, improvement and production of complex proteins; especially heteromeric proteins. The Company's work with the filamentous fungi Neurospora crassa has resulted in significant advances in three important areas of biotechnology: directed evolution, combinatorial biology and recombinant protein expression.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.